Changyu Pharma develops pharmaceutical products for the Chinese market.
$35MSeries D
Investor undisclosed
A $35M Series D for a China-focused pharma company in mid-2026 suggests domestic biotech is still attracting late-stage capital despite macro headwinds—but the undisclosed investor list is a yellow flag that this might be government-backed or a down round. If you're building biotech infrastructure (manufacturing, regulatory, supply chain), watch whether Changyu's next moves are geographic expansion or pure domestic consolidation; that'll tell you if Chinese pharma is ready to compete globally or just optimizing for domestic margin.